ClinicalTrials.gg
RecruitingNCT06174220TaRGETUpdated Mar 12, 2026

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

A Phase 2 interventional study of Tideglusib and Placebo in Arrhythmogenic Cardiomyopathy and Arrhythmogenic Right Ventricular Cardiomyopathy, sponsored by Hamilton Health Sciences Corporation. Recruiting at 17 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Hamilton Health Sciences Corporation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.

Read the detailed description

Arrhythmogenic cardiomyopathy (ACM) is a heritable form of structural heart disease characterized by myocardial fibrosis that confers vulnerability to malignant ventricular arrhythmias and sudden cardiac death (SCD). A subgroup of cases preferentially involves the right ventricle and is termed arrhythmogenic right ventricular cardiomyopathy (ARVC). Although an increasingly diverse set of genes have been implicated in ACM, its most prominent genetic culprits are constituents of the desmosome, a specialized cellular structure within the intercalated disc that mediates intercellular adhesion. An additional ACM genetic subtype develops secondary to the TMEM43-p.S358L variant and is associated with an aggressive clinical phenotype, particularly among males.

Despite dramatic progress in unravelling the genetic underpinnings of ACM, insight into its pathophysiology remains modest. A lack of understanding of its operative biological pathways has rendered development of tailored treatments challenging, leading to approaches to medical therapy being largely adopted from those utilized for more common forms of cardiomyopathy. An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for all ACM patients considered high risk for malignant ventricular arrhythmias, however does not address its underlying pathophysiology. Subsequent prevention of painful ICD shocks for ventricular tachycardia often requires interventions that may carry modest efficacy and significant risks for adverse events, including anti-arrhythmic drugs and invasive combined endo- and epicardial catheter ablation procedures.

In 2014, a high-throughput screen of a library of bioactive compounds against a zebrafish model of ACM identified a small molecule classified as a glycogen synthase kinase-3 (GSK3) inhibitor that successfully prevented and rescued the phenotype, findings that have subsequently been reproduced in a series of ACM murine models. GSK3 is an enzyme that modulates the activity of a broad spectrum of intracellular signaling pathways, including the canonical Wnt/β-catenin pathway, whose suppression has been suggested to exert an important role in ACM pathogenesis.

Tideglusib is an oral GSK3β inhibitor with an established safety profile in humans. Driven by promising findings observed for tideglusib in ACM mouse models, we now seek to evaluate its potential efficacy in a randomized clinical trial involving genotype positive ACM patients.

02

Conditions studied

  • Arrhythmogenic Cardiomyopathy
  • Arrhythmogenic Right Ventricular Cardiomyopathy

Keywords

  • sudden cardiac death, ventricular cardiomyopathy, genetics, arrhythmia
03

In context

Arrhythmogenic Right Ventricular Dysplasia

49 studies on the registry are indexed under Arrhythmogenic Right Ventricular Dysplasia; 29 are open to participants now.

This study's planned enrollment of 120 is above the median of 22 across 15 interventional studies indexed under Arrhythmogenic Right Ventricular Dysplasia.

Browse Arrhythmogenic Right Ventricular Dysplasia studies →

Lead sponsor

Hamilton Health Sciences Corporation is the lead sponsor of 242 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP*) rare variant OR the TMEM43-p.S358L variant

    *JUP carriers must be homozygous or compound heterozygous

  • Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor
  • Clinical ACM diagnosis or recognition of genetic carrier status for ≥ 6 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • class IV heart failure
  • Ventricular scar secondary to coronary artery disease
  • Initiation, cessation, or dose change of a Class I or III anti-arrhythmic drug in the 3 months prior to screening
  • Any potentially harmful chronic liver disease
  • value > 2X the reference range at Screening
  • Total value greater than the upper limit of the normal reference range at Screening, unless documented Gilbert's syndrome. For individuals with Gilbert's syndrome, total bilirubin value greater than 2-fold the upper limit of the normal reference range at Screening.
  • A history of alcohol or illicit substance use disorders
  • Regular and long-term use of strong inhibitors, including clarithromycin, telithromycin, ketoconazole, itraconazole, posaconazole, nefazodone, idinavir and ritonavir
  • Serum creatinine > 150 micromole/L or ≤ 60 mL/min (according to Cockcroft-Gault formula) at Screening
  • Pregnant at time of enrollment and women of childbearing age who do not use a highly effective form of
  • Males, engaged in sexual relations with a female of , not using an acceptable contraceptive method if not surgically sterile
  • Patients unwilling to provide or comply with follow-up
  • to tideglusib or any components of its formulation, including allergy to strawberry
  • Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window e.g. warfarin and digoxin
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Tideglusib

    Randomization to Tideglusib 1g po daily or matching placebo

    Drug: Tideglusib

  • Placebo comparator
    Placebo

    Randomization to matching placebo 1g po daily

    Drug: Placebo

Interventions

  • Tideglusib 1g po daily

  • DrugPlacebo

    Matching placebo 1g po daily

06

What researchers measure

Primary outcomes

  1. PVC burden

    Change in mean PVC count per 24 hours on 7-day Holter

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Ventricular strain

    Change in ventricular strain on echocardiography

    Time frame: Baseline and 6 months

  2. Implantable cardioverter-defibrillator (ICD) therapies

    Number of ICD therapies (shock or anti-tachycardia pacing)

    Time frame: Baseline and 6 months

  3. Sustained ventricular tachycardia (VT) events

    Number of sustained VT events (defined as symptomatic or duration \> 30 seconds and \> 100bpm)

    Time frame: Baseline and 6 months

07

Study locations

10 of 17 sites recruiting
  • University of Calgary
    Calgary, Alberta T2N 2T9, Canada
    Recruiting
    • Erkan Ilhan · Contacterkan.ilhan@ucalgary.ca · 403-210-6047
    • Erkan Ilhan, MD · Principal investigator
    • Patrick Champagne, MD · Sub investigator
  • University of British Columbia
    Vancouver, British Columbia V6Z 1Y6, Canada
    Recruiting
    • Thomas Roston · Contactrostonm@alumni.ubc.ca · 604-682-2344
    • Thomas M Roston, MD PhD · Principal investigator
    • Zachary Laksman, MD MSc · Principal investigator
    • Andrew D Krahn, MD · Principal investigator
    • Gnalini Sathananthan, MD · Sub investigator
  • Victoria Cardiac Arrhythmia Trials Inc.
    Victoria, British Columbia V8Z 0B9, Canada
    Recruiting
    • May Woodburn · Contactmwoodburn@catrials.org · 250-595-0400
    • Martin van Zyl, MD · Principal investigator
    • Karan Shetty, MD · Sub investigator
  • NL Health Services
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
    Recruiting
    • Stephen Duffett · Contactstephen.duffett@easternhealth.ca · 709-752-4636
    • Stephen Duffett, MD · Principal investigator
    • Sean Connors, MD · Principal investigator
    • Kathy Hodgkinson, PhD · Principal investigator
    • Ashar Pirzada, MD · Sub investigator
  • Nova Scotia Health
    Halifax, Nova Scotia B3H 2Y9, Canada
    Recruiting
    • Victoria Newman · Contactvictoria.newman@nshealth.ca · 902-473-5341
    • David Lee, MD · Principal investigator
    • Ciorsti MacIntyre, MD · Principal investigator
    • Daniel Belliveau, MD · Sub investigator
  • Hamilton General Hospital
    Hamilton, Ontario L8L 2X2, Canada
    Recruiting
    • Jeff Healey · Contactjeff.healey@phri.ca · 905-527-0271
    • Jeff S Healey, MD · Principal investigator
    • Javier Ganame, MD · Sub investigator
    • William F McIntyre, MD PhD FRCPC · Sub investigator
  • Kingston General Hospital
    Kingston, Ontario K7L 2V7, Canada
    Not yet recruiting
    • Chris Simpson, MD · Principal investigator
    • Amar Thakrar, MD · Sub investigator
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
    Recruiting
  • Newmarket Electrophysiologist Research Group 'NERG'
    Newmarket, Ontario L3Y 2P9, Canada
    Not yet recruiting
    • Mouhannad Sadek, MD · Principal investigator
    • Molly Thangaroopan, MD · Sub investigator
  • University of Ottawa Heart Institute
    Ottawa, Ontario K1Y 4W7, Canada
    Not yet recruiting
    • Simon Hansom, MD · Principal investigator
    • Martin Green, MD · Principal investigator
    • Lawrence Lau, MD · Sub investigator
  • Heart Health Institute Research Inc
    Scarborough Village, Ontario M1E 4B9, Canada
    Recruiting
    • Emily Magimaidoss · Contactemagimaidoss@hearthealthinstitute.net · 416-281-9499
    • Bhavanesh Makanjee, MD · Principal investigator
    • Derek Yung, MD · Principal investigator
    • Natalie Ho, MD · Sub investigator
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
    Not yet recruiting
    • Christopher Cheung, MD · Principal investigator
    • Idan Roifman, MD · Sub investigator
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
    Not yet recruiting
    • Paul Angaran, MD · Principal investigator
    • Geraldine Ong, MD · Sub investigator
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
    Recruiting
    • Jeremie Cortial · Contactjeremie.cortial@icm-mhi.org · 514-376-3330
    • Julia Cadrin-Tourigny, MD PhD · Principal investigator
    • Rafik Tadros, MD PhD · Principal investigator
    • Marie Chaix, MD · Sub investigator
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
    • Jacqueline Joza, MD · Principal investigator
    • Michael Chetrit, MD · Sub investigator
  • Hopital du Sacré-Coeur de Montréal
    Montreal, Quebec H4J 1C5, Canada
    Not yet recruiting
    • Leila Laroussi, MD · Principal investigator
    • Alexios Hadjis, MD · Principal investigator
    • Nadia Boule-Laghlazi, MD · Sub investigator
  • University Institute of Cardiology and Pneumology of Quebec
    Québec, Quebec G1V 4G5, Canada
    Recruiting
08

References and documents

Publications

  • Krahn AD, Wilde AAM, Calkins H, La Gerche A, Cadrin-Tourigny J, Roberts JD, Han HC. Arrhythmogenic Right Ventricular Cardiomyopathy. JACC Clin Electrophysiol. 2022 Apr;8(4):533-553. doi: 10.1016/j.jacep.2021.12.002. PubMed 35450611 ↗
  • Asimaki A, Kapoor S, Plovie E, Karin Arndt A, Adams E, Liu Z, James CA, Judge DP, Calkins H, Churko J, Wu JC, MacRae CA, Kleber AG, Saffitz JE. Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Transl Med. 2014 Jun 11;6(240):240ra74. doi: 10.1126/scitranslmed.3008008. PubMed 24920660 ↗
  • Chelko SP, Asimaki A, Andersen P, Bedja D, Amat-Alarcon N, DeMazumder D, Jasti R, MacRae CA, Leber R, Kleber AG, Saffitz JE, Judge DP. Central role for GSK3beta in the pathogenesis of arrhythmogenic cardiomyopathy. JCI Insight. 2016 Apr 21;1(5):e85923. doi: 10.1172/jci.insight.85923. PubMed 27170944 ↗
  • Roberts JD, Murphy NP, Hamilton RM, Lubbers ER, James CA, Kline CF, Gollob MH, Krahn AD, Sturm AC, Musa H, El-Refaey M, Koenig S, Aneq MA, Hoorntje ET, Graw SL, Davies RW, Rafiq MA, Koopmann TT, Aafaqi S, Fatah M, Chiasson DA, Taylor MR, Simmons SL, Han M, van Opbergen CJ, Wold LE, Sinagra G, Mittal K, Tichnell C, Murray B, Codima A, Nazer B, Nguyen DT, Marcus FI, Sobriera N, Lodder EM, van den Berg MP, Spears DA, Robinson JF, Ursell PC, Green AK, Skanes AC, Tang AS, Gardner MJ, Hegele RA, van Veen TA, Wilde AA, Healey JS, Janssen PM, Mestroni L, van Tintelen JP, Calkins H, Judge DP, Hund TJ, Scheinman MM, Mohler PJ. Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. J Clin Invest. 2019 Jul 2;129(8):3171-3184. doi: 10.1172/JCI125538. eCollection 2019 Jul 2. PubMed 31264976 ↗
  • Padron-Barthe L, Villalba-Orero M, Gomez-Salinero JM, Dominguez F, Roman M, Larrasa-Alonso J, Ortiz-Sanchez P, Martinez F, Lopez-Olaneta M, Bonzon-Kulichenko E, Vazquez J, Marti-Gomez C, Santiago DJ, Prados B, Giovinazzo G, Gomez-Gaviro MV, Priori S, Garcia-Pavia P, Lara-Pezzi E. Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3beta. Circulation. 2019 Oct;140(14):1188-1204. doi: 10.1161/CIRCULATIONAHA.119.040366. Epub 2019 Sep 5. PubMed 31567019 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 18, 2023
StartActual
Mar 21, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06174220
Collaborators
Canadian Institutes of Health Research (CIHR), Canadian SADS, AMO Pharma Limited, Hearts in Rhythm Organization (HiRO), Population Health Research Institute
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Mar 21, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Mar 12, 2026

Study contacts

Jason Roberts, MD MAS
Contact
jason.roberts@phri.ca
905-521-2100 ext. 40354
Maha Mushtaha
Contact
maha.mushtaha@phri.ca
Jason D Roberts, MD MAS
principal investigator · McMaster University and Population Health Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tideglusib

Start the discussion